This review demonstrates the potential benefits of anti-angiogenic therapy in combination with chemotherapy and immunotherapy (AIC) as a viable strategy for treating EGFR-mutant, TKI-resistant, and de novo metastatic disease in NSCLC patients. Here, EGFR is linked to non-small cell lung carcinoma.